ERBB2 and breast carcinoma: Built upon our finding that Melatonin decreases HER2 protein stability in this study, we next investigated whether Melatonin could potentiate the therapeutic effect of the pan-HER kinase inhibitor Neratinib in the treatment of HER2+ breast cancer cells.